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Abstract: Head and neck squamous cell carcinomas (HNSCC) have a high mortality rate, although
several potential therapeutic targets have already been identified. Gonadotropin-releasing hormone
receptor (GnRH-R) expression is less studied in head and neck cancers, hence, we investigated the
therapeutic relevance of GnRH-R targeting in HNSCC patients. Our results indicate that half of
the patient-derived samples showed high GnRH-R expression, which was associated with worse
prognosis, making this receptor a promising target for GnRH-based drug delivery. Photodynamic
therapy is a clinically approved treatment for HNSCC, and the efficacy and selectivity may be enhanced
by the covalent conjugation of the photosensitizer to a GnRH-R targeting peptide. Several native
ligands, gonadotropin-releasing hormone (GnRH) isoforms, are known to target GnRH-R effectively.
Therefore, different 4Lys(Bu) modified GnRH analogs were designed and conjugated to protoporphyrin
IX. The receptor binding potency of the novel conjugates was measured on human pituitary and
human prostate cancer cells, indicating only slightly lower GnRH-R affinity than the peptides.
The in vitro cell viability inhibition was tested on Detroit-562 human pharyngeal carcinoma cells that
express GnRH-R in high levels, and the results showed that all conjugates were more effective than
the free protoporphyrin IX.
Keywords: GnRH-R; GnRH; protoporphyrin; targeted drug delivery; conjugate; photodynamic
therapy; head and neck cancer
1. Introduction
Photodynamic therapy (PDT) is a clinically approved treatment for malignant tumors, such
as head and neck, skin, breast, and bladder cancers. It combines nontoxic components as follows:
A photosensitizer, light, and oxygen. The photosensitizing agent can passively accumulate into tumor
cells, but it is nontoxic in the absence of light. If it is irradiated at a wavelength corresponding to an
absorbance band of the sensitizer in the presence of molecular oxygen, a series of events lead to direct
tumor cell death. Electron and energy transfers generate highly reactive radicals or singlet oxygen
(1O2) that rapidly react with biomolecules leading to cell death via apoptosis or necrosis. Selectivity is
derived from both the ability of photosensitizers to localize in the tumor and the precise delivery of light
to the treated sites. Unfortunately, most commonly applied photosensitizers used for PDT accumulate
not only in tumors, but also in healthy tissues, resulting in severe side effects like prolonged skin and
eye photosensitivity [1–4]. Therefore, targeting studies in which the photosensitizers are covalently
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attached to various molecules (e.g., peptides) that have a specific affinity to receptors overexpressed on
tumors are currently intensively investigated [5].
Gonadotropin-releasing hormone (GnRH) receptors are overexpressed on several tumor cells.
These receptors are not only expressed by reproductive organ-derived tumors (ovarian, endometrial,
prostatic, and breast cancers), but also oral and laryngeal cancers, renal carcinomas, brain tumors,
melanomas, liver, pancreatic and colon carcinomas, and non-Hodgkin lymphomas [6]. One of the
native ligands of the GnRH receptors (GnRH-R) found in humans is GnRH-I. This hormone peptide is
a decapeptide (<EHWSYGLRPG-NH2, where <E is pyroglutamic acid) synthesized and released in the
hypothalamus and plays a pivotal role in the control of vertebral reproduction by regulating gonadal
activity and stimulating the secretion of pituitary luteinizing hormone (LH) and follicle stimulating
hormone (FSH) [7]. GnRH-II (<EHWSHGWYPG-NH2) is another isoform, mainly expressed in the
kidneys, bone marrow, and prostate [8], and is found to be a neuromodulator that stimulates sexual
behavior [9]. GnRH-III (<EHWSHDWKPG-NH2) was originally isolated from lamprey. It binds to
both type I and type II GnRH receptors [10], moreover it can inhibit proliferation of different cancer
cells without significant hormonal activity [11].
The N- and C-terminal parts of GnRH (amino acids 1–4 and 9–10), which are essential for receptor
binding and activation, are conserved [9], but the amino acids 5–8 can be changed without significant
loss of efficacy. In the sequence of GnRH-I and GnRH-II, the glycine in position 6 can be replaced by
D-lysine, which serves as conjugation site, increases enzymatic stability, and enhances the agonistic
effect [12]. 6D-Lys in GnRH-I and GnRH-II analogs was used for daunorubicin (Dau) conjugation
directly or through an enzyme-labile spacer with oxime linkage. It was demonstrated that the long-term
cytotoxic effect of these conjugates was comparable with the free drug [13]. Schally and his coworkers
developed AN-152, where the hemiglutarate derivative of doxorubicin was conjugated to the side
chain of 6D-Lys in GnRH-I analog, resulting in an ester bond between the drug molecule and the
peptide [14]. Extensive in vitro [15,16] and in vivo [17–20] studies were done and AN-152 reached
clinical trials [21,22], but it failed in phase III since it could not improve overall survival, progression-free
survival, objective response rate, clinical benefit rate, or adverse events compared to doxorubicin as a
second line therapy for advanced endometrial cancers [23]. AN-152 was also used to target oral (KB)
and laryngeal (HEp-2) carcinoma cells and was found to be very effective on both GnRH-R expressing
tumors. In addition, it could overcome resistance to doxorubicin [24]. Rahimipour et al. have already
conjugated protoporphyrin IX to GnRH-I [6D-Lys] and the selective receptor mediated phototoxicity
could be demonstrated on a αT3-1 pituitary gonadotrope cell line [25]. In another study, carminic acid,
a hydroxyanthraquinone derivative, was conjugated to GnRH-I [6D-Lys] to gain a phototoxic molecule
and retained bioactivity, and formation of reactive oxygen species upon irradiation was observed [26].
In the case of GnRH-III, the natural sequence contains two side chain functional groups (6Asp
and 8Lys) that can serve as conjugation sites. Previous studies showed that modification of the side
chain of 8Lys did not change the antiproliferative activity or the receptor binding [27] and, furthermore,
it reduced the endocrine effect [28]. Hence, this position can be used for further conjugations. It was
also indicated that the replacement of 4Ser to Lys or Lys(Ac) results in similar antitumor activity and
endocrine effect [29]. Moreover, the modification of the 4Lys side chain with butyric acid (Lys(Bu)),
a short-chain fatty acid, significantly increased the stability against chymotrypsin and the in vitro
cellular uptake of oxime bond-linked Dau-GnRH-III bioconjugates [30] and led to enhanced in vivo
antitumor activity [31]. These results presume that the same modification (4Ser→ 4Lys(Bu)) in the
sequence of GnRH-I and GnRH-II can result in similar advantageous effects.
Protoporphyrin IX (PpIX) is an endogenous photosensitizer and it is the last intermediate in heme
biosynthesis. Endogenous PpIX-based strategies have been approved by the FDA for treating cancer,
where δ-aminolevulinic acid (ALA, the first intermediate in heme biosynthesis) is administered orally
or locally to generate PpIX biosynthesis. Unfortunately, the generated PpIX does not only accumulate
in cancer cells but also in healthy cells, such as the marrow, the circulating erythrocytes, and the liver,
causing photosensitivity or liver damage [32]. PpIX has two carboxyl groups that are suitable for the
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conjugation of a targeting moiety, giving the opportunity to increase the selectivity. Hence recently, PpIX
has also been studied as exogenous photosensitizer conjugated to peptides [25,33], nanoparticles [34–36],
or quantum dots [37] and encapsulated into polymer dendrimers [38,39]. In this study, PpIX was
conjugated to the novel 4Lys(Bu) modified GnRH-analogs to overcome undesirable side-effects by
enhancing the selectivity and efficacy of the treatment. Our aim was to compare the effectiveness of
the different GnRH conjugates and to prepare more effective compounds than PpIX. PDT can be used
in those types of cancer that are easily accessible for the irradiation, such as head and neck cancers,
melanomas, or lung cancers. Hence, in the present study, GnRH receptor expression was investigated in
patent-derived head and neck squamous cell carcinoma (HNSCC) samples by immunohistochemistry.
Based on the positive results, our novel bioconjugates were tested in vitro on Detroit-562 human
pharyngeal carcinoma cells that have already been demonstrated to express GnRH receptors in high
levels [40].
2. Results
2.1. GnRH receptor (GnRH-R) Expression in Patient-Derived Head and Neck Squamous Cell Carcinoma
(HNSCC) Samples
From the 60 tumor samples, 8 (13.3%) cases showed low, 25 (41.7%) cases showed moderate,
and 27 (45.0%) cases showed high GnRH-R expression (Figures 1 and 2A). For statistical analysis,
scores were dichotomized along different threshold values. The most reproducible threshold for the
assessor was set up when scores of 1 and 2 were considered low protein expression, whereas scores of
3 were taken as high protein expression.
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Figure 1. Examples of immunostaining in head and neck squamous cell carcinomas (HNSCC). (A) Low 
GnRH-R expression; (B) moderate GnRH-R expression; (C) high GnRH-R expression. (Magnification: 
×40) 
The GnRH-R status did not correlate with tumor size (p = 0.722), tumor localization (p = 0.527), 
lymph node metastasis (p = 0.126), stage (p = 0.913), and disease-specific survival (DSS, p = 0.423). 
However, the increase in GnRH-R expression was associated with worse prognosis (Figure 2B). 
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(A) Low GnRH-R expressi n; (B) moderat GnRH-R expression; (C) high GnRH-R expression.
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The GnRH-R status did not correlate with tumor size (p = 0.722), tumor localization (p = 0.527),
lymph node metastasis (p = 0.126), stage (p = 0.913), and disease-specific survival (DSS, p = 0.423).
However, the increase in GnRH-R expression was associated with worse prognosis (Figure 2B).
2.2. Peptide Synthesis
GnRH-I and GnRH-II analogs (<EHWSYkLRPG-NH2, 1; <EHWK(Bu)YkLRPG-NH2, 2;
and <EHWK(Bu)HkWYPG-NH2, 3) were prepared using D-Lys in position 6. Methyl
ester protected aspartic acid was used in position 6 in case of the GnRH-III analog
(<EHWK(Bu)HD(OMe)WKPG-NH2, 4) to ensure that protoporphyrin IX (PpIX) can couple only to 8Lys.
It was shown that this protecting group did not influence the efficacy of GnRH-III significantly [41].
For the synthesis of the butyric acid modified analogs, selectively protected lysine derivative was
incorporated in position 4. After the synthesis of the backbones, this selectively removable protecting
group was cleaved and the free ε-amino group of the lysine was reacted with butyric anhydride.
2.3. GnRH-Protoporphyrin IX Conjugate Synthesis
The amide bond formation between the ε-amino groups of the appropriate lysine residues and
one of the carboxyl groups of PpIX was carried out in solution (Figure 3), resulting in compounds
5–8 (Table 1). Since protoporphyrin is a photolabile compound, these reactions were performed in
darkness. Only 1:1 peptide-PpIX conjugates were formed (no dimer conjugates—2:1 peptide-PpIX—
could be observed) and only a small amount of water-lost side-product was detected in case of the
GnRH-I analogs, which could be hydrolyzed under basic conditions to the desired product, presuming
an extra ester bond formation between the other carboxyl group of PpIX and the tyrosine side chain.
This side product was not detected in the case of GnRH conjugates without Tyr content.
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The coupling was performed in DMF with PyBOP (benzotriazol-1-yl-oxytripyrrolidinophosphonium
hexafluorophosphate) in the presence of DIPEA (diisopropylethylamine) (16 h, r.t.).
Table 1. The synthesized compounds: the linkable targeting peptides (GnRH analogs; 1–4) and their
PpIX conjugated derivatives (5–8).
Code Peptide Code Conjugate
1 GnRH-I[6D-Lys] 5 GnRH-I[6D-Lys(PpIX)]
2 GnRH-I[4Lys(Bu), 6D-Lys] 6 GnRH-I[4Lys(Bu), 6D-Lys(PpIX)]
3 GnRH-II[4Lys(Bu), 6D-Lys] 7 GnRH-II[4Lys(Bu), 6D-Lys(PpIX)]
4 GnRH-III[4Lys(Bu), 6Asp(OMe)] 8 GnRH-III[4Lys(Bu), 6Asp(OMe), 8Lys(PpIX)]
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2.4. Receptor Binding Potency of the Novel Compounds
The binding potency of the GnRH analogs and the GnRH-PpIX conjugates to human pituitary
and human prostate cancer cells, that express GnRH-R in high concentration, was investigated
by ligand competition assay. The displacement of 125I-radiolabelled GnRH-I agonist triptorelin
([125I]-[6D-Trp]-GnRH-I) by the synthesized compounds was determined. At a concentration of 10−6 M
unconjugated PpIX and several other peptides structurally related or structurally and/or functionally
unrelated to GnRH, such as somatostatin-14, hGHRH, EGF, IGF-I, glucagon and VIP did not inhibit the
binding of [125I]-[6D-Trp]-GnRH-I. The data showed (Table 2) that the 4Lys(Bu) modified GnRH analogs
(2–4) could bind GnRH-R with similar potency than GnRH-I[6D-Lys] (1), while the PpIX conjugation
decreased the receptor binding affinity in all cases. Nevertheless, the peptide-PpIX conjugates (5–7)
had only slightly lower GnRH-R affinity, except compound 8 that had two orders of magnitude lower
binding affinity to the receptors than the free peptide.
Table 2. Receptor binding potency of the GnRH analogs and the GnRH-PpIX conjugates measured by
the inhibition of [125I]-[6D-Trp]-GnRH-I binding to the membranes of human pituitary and human
prostate cancer cells.
Code Compound
IC50 Values/nM
Human Pituitary Human Prostate Cancer
1 GnRH-I[6D-Lys] 6.44 ± 0.95 4.31 ± 0.83
2 GnRH-I[4Lys(Bu), 6D-Lys] 9.70 ± 1.07 8.61 ± 1.08
3 GnRH-II[4Lys(Bu), 6D-Lys] 5.56 ± 1.07 4.65 ± 0.31
4 GnRH-III[4Lys(Bu), 6Asp(OMe)] 7.27 ± 0.92 6.56 ± 1.11
5 GnRH-I[6D-Lys(PpIX)] 36.29 ± 3.17 42.67 ± 7.04
6 GnRH-I[4Lys(Bu), 6D-Lys(PpIX)] 42.30 ± 4.27 41.80 ± 5.74
7 GnRH-II[4Lys(Bu), 6D-Lys(PpIX)] 79.40 ± 8.88 84.50 ± 10.30
8 GnRH-III[4Lys(Bu), 6Asp(OMe), 8Lys(PpIX)] 288.6 ± 17.3 341.4 ± 21.1
2.5. UV-Vis Absorbance
The UV-Vis spectra of the conjugates were measured in PBS-acetonitrile mixture to determine
any changes in the absorbance compared to protoporphyrin. There was no significant change
observed in the spectra (Figure 4), indicating that the conjugation did not change the features of
PpIX. (As demonstrated in Figure S5, the peptides alone did not have a significant contribution to the
absorbance above 300 nm in the UV spectra.)Int. J. Mol. Sci. 2019, 20, x 6 of 17 
 
 
Figure 4. UV-Vis spectra of PpIX and the peptide-PpIX conjugates. 
2.6. GnRH-R Expression of Detroit-562 Human Pharyngeal Carcinoma Cells 
Detroit-562 pharynx cells were selected for the in vitro biological studies of the GnRH-PpIX 
conjugates. This cell line has already been proved to express GnRH-R [40] and our measurements, 
using confocal laser scanning microscopy, also demonstrated high expression level of GnRH-R 
(Figure 5, GnRH-R in permeabilized cells). A significant number of receptors was found in non-
permeabilized cells (Figure 5, GnRH-R in non-permeabilized cells), as well, which may refer to the 
presence of GnRH-R in the cell membrane. 
 
Figure 5. GnRH-R in Detroit-562 cells. The measurements confirm the high GnRH-R expression of 
Detroit-562 cells (GnRH-R in permeabilized cells) and the high number of receptors on non-
permeabilized cells (nuclei: blue–DRAQ5; GnRH-R: red–Alexa Fluor 594). 
2.7. Optimization of the Irradiation and Incubation Time 
GnRH-I[6D-Lys(PpIX)] (compound 5) was used for the optimization of the conditions of the cell 
viability inhibition assays. First, the irradiation time was optimized. Detroit-562 pharyngeal cells 
Figure 4. UV- is spectra of P I a the peptide-PpIX conjugates.
Int. J. Mol. Sci. 2019, 20, 5027 6 of 17
2.6. GnRH-R Expression of Detroit-562 Human Pharyngeal Carcinoma Cells
Detroit-562 pharynx cells were selected for the in vitro biological studies of the GnRH-PpIX
conjugates. This cell line has already been proved to express GnRH-R [40] and our measurements,
using confocal laser scanning microscopy, also demonstrated high expression level of GnRH-R (Figure 5,
GnRH-R in permeabilized cells). A significant number of receptors was found in non-permeabilized
cells (Figure 5, GnRH-R in non-permeabilized cells), as well, which may refer to the presence of
GnRH-R in the cell membrane.
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Figure 5. GnRH-R in Detroit-562 cells. The measurements confirm the high GnRH-R expression
of Detroit-562 cells (GnRH-R in permeabilized cells) and the high number of receptors on
non-permeabilized cells (nuclei: blue–DRAQ5; GnRH-R: red–Alexa Fluor 594).
2.7. Optimization of the Irradiation and Incubati
GnRH-I[6D-Lys(PpIX)] (compound 5) s s f r t e optimization of the conditions of th cell
viability inhibition assays. First, the irradiation time was optimized. Detroit-562 pharyngeal cells were
treated with the peptide-PpIX conjugate for 5 h, the unbound conjugate was washed out, and then
the cells were irradiated for 0, 2, 10, or 30 min followed by 72 h of further incubation (Figure 6A).
The obtained results showed that the conjugate was non-toxic in the absence of light, while irradiation
for 2 min resulted in 50% cell viability inhibition in sub-micromolar concentration. There was no
significant difference between the 10 and the 30 min irradiation; both were already very effective in
0.1 µM concentration (~98% cell viability inhibition), therefore 10 min irradiation was chosen for the
further experiments. Moreover, this length of time may also be more favorable in the subsequent
in vivo studies.
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Afterwards, the incubation time was optimized. The cells were incubated either with compound
5 or with PpIX for 1, 3, or 5 h and irradiated for 10 min. As demonstrated in Figure 6B, a longer
incubation time with compound 5 resulted in higher activity. On the contrary, there was no significant
difference between the effect of the incubation times in case of the protoporphyrin (Figure 6C). Based on
these results, the 5 h incubation time was chosen for the further measurements.
2.8. In Vitro Cell Viability Inhibition Effect of the Peptide-PpIX Conjugates
The cell viability inhibition of the synthesized GnRH-PpIX conjugates was measured on Detroit-562
cells using the previously optimized conditions (5 h treatment, 10 min irradiation). Figure 7 shows
that all conjugates were more active than PpIX. All were very effective (90–95% inhibition) in 0.25 µM,
while PpIX showed only ~50% inhibition at this concentration. Conjugates 5 and 7 were the most
active compounds. These showed >90% cell viability inhibition at 0.1 µM. Conjugates 6 and 8 were
less effective, as both analogs showed 65–70% inhibition at 0.1 µM concentration. These results are also
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confirmed by the calculated IC50 values (Table 3). The peptides (1–4) alone did not show cell viability
inhibition, even at 10 µM concentration (Figure S6).
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Table 3. Calculated IC50 values of the prepared conjugates and PpIX.
Code Compound IC50 Values/nM
5 GnRH-I[6D-Lys(PpIX)] 62.3 ± 5.9
6 GnRH-I[4Lys(Bu), 6D-Lys(PpIX)] 89.8 ± 19.4
7 GnRH-II[4Lys(Bu), 6D-Lys(PpIX)] 71.1 ± 6.2
8 GnRH-III[4Lys(Bu), 6Asp(OMe), 8Lys(PpIX)] 81.8 ± 12.6
PpIX Protoporphyrin IX 209.3 ± 119.5
3. Discussion
Head and eck squamous cell carcinomas (HNSCC) account for ~4% of all malignancies worldwide.
HNSCC has a high mort lity rate and is more common among men a d th se ov r the age of 50 [42].
Several potential th rapeutic targets have already been identified (e.g., epid rmal growth factor receptor
(EGFR)) [43,44], howeve , targeted therapy of HNSCC is still not well established due to acquired
resi t nce [45]. H nce, finding other appropriate molecular tar ets is essential to achiev personalized
targeted therapy. GnRH receptor (GnRH-R) pres nce has already been proved by displacem nt binding
assays on KB oral and HEp-2 laryngeal carcinoma cells [24], while high GnRH-R expression and cell
surface localization, moreover effective cell lar uptake of G RH analogs, has be n demonstr ted
on Detroit-562 hum n pharynx tumo c lls [40]. Since no comprehensive research has been done so
far about G RH-R in HNSCC, w investigated 60 patient-derived tumor samples and t sted them
for GnRH-R. The result i icat at 45.0% of these tumors howed hig GnRH-R expr ssion,
which makes this receptor a promising target in the treatment of HNSCC. Mor over, we checked
several clinicopathological factors in cor elation of GnRH-R status and we found that higher Gn H-R
expression was associated with worse prognosis. We also strengthened that the Detroit-562 human
pharyngeal carcinoma cells express GnRH-R in high levels and a high proportion of receptors is
found on non-permeabilized cells as well, implying that these receptors may be localized in the cell
membrane, proving that these cells are appropriate for GnRH-R targeted in vitro studies.
PDT is a clinically approved treatment for HNSCC since all types (oropharynx, larynx,
hypopharynx) are easily accessible for irradiation. The covalent conjugation of a photosensitizer to
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a proper delivery molecule that targets GnRH-R may enhance the efficacy and selectivity of PDT.
To find the most effective targeting moiety we designed three novel butyric acid modified GnRH
derivatives (4Lys(Bu) modification) and compared them to the generally used GnRH-I superagonist
GnRH-I[6D-Lys]. The receptor binding potency of the novel peptides (2–4) was similar to the control
peptide (1), presuming that all analogs have similar targeting capability. Then, PpIX as photosensitizer
was coupled to the GnRH-analogs via amide bond under controlled conditions to get the well-defined
1:1 conjugates solely. We demonstrated that the conjugation of PpIX to the peptides did not affect
the UV-Vis absorbance of the photosensitizer. These GnRH-PpIX conjugates showed lower receptor
binding affinity than the free peptides, probably due to steric hindrance, however, this was only a
slight difference in case of compounds 5–7. Conjugate 8 showed two orders of magnitude difference
compared to 4. It is worth mentioning that GnRH-I and GnRH-II have U shape structures and the
photosensitizer attached to the D-Lys in position 6 cannot interfere with the termini of the peptides that
take part in the receptor recognition. In contrast, GnRH-III shows, rather, a flexible extended structure.
Therefore, the attachment of a bulky compound to Lys in position 8 might significantly decrease the
binding potency of the conjugate to the receptor [46].
After the optimization of the in vitro cell viability assay conditions (5 h of incubation time and
10 min of irradiation) we tested all GnRH-PpIX conjugates on Detroit-562 cells. We could demonstrate
that all synthesized conjugates were more effective than the free PpIX. Compounds 5 and 7 were the
most active conjugates. These showed an outstanding cell viability inhibition effect already at 0.1 µM,
while 6 and 8 were less effective. All conjugates showed >90% cell viability inhibition at 0.25 µM;
however, PpIX was not very effective in sub-micromolar concentration. These results correspond well
with the receptor binding affinity of the conjugates. According to the results, the 4Lys(Bu) modified
GnRH-II analog showed similar efficacy to the control GnRH-I analog, while the modified GnRH-I
analog and the GnRH-III derivative were just slightly less effective.
In this work, we demonstrated that GnRH-R may be an appropriate target in the treatment of
HNSCC and, to prove this statement, four different GnRH-PpIX conjugates were synthesized for PDT.
The in vitro cell viability inhibition was studied on a pharyngeal cell line and our results confirmed
that these conjugates may be used later in PDT of HNSCC. All conjugates were more effective than the
free PpIX, showing the importance and advantage of targeted therapy in PDT. Based on these results,
we plan to test the two best conjugates in in vivo models as well.
4. Materials and Methods
4.1. Chemicals
All amino acid derivatives, the Fmoc-Rink Amide MBHA resin, N,N′-diisopropylcarbodiimide
(DIC), and trifluoroacetic acid were purchased from Iris Biotech GmBH (Marktredwitz, Germany).
The 1-hydroxybenzotriazole hydrate (HOBt), triisopropylsilane (TIS), diisopropylethylamine (DIPEA),
butyric anhydride, hydrazine hydrate, and protoporphyrin IX (PpIX) were obtained from Sigma
Aldrich Kft. (Budapest, Hungary). The 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) was from TCI Europe
N.V. (Zwijndrecht, Belgium). Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate
(PyBOP) was obtained from Bachem AG (Bubendorf, Switzerland), while piperidine was purchased
from Molar Chemicals Kft (Budapest, Hungary). All solvents used for synthesis and purification were
purchased from VWR International Kft. (Debrecen, Hungary). All reagents and solvents were of
analytical grade or the highest available purity.
For the in vitro biological assays, EMEM (Eagle’s minimum essential medium), sodium pyruvate,
MycoZap, and PBS were obtained from Lonza Group Ltd. (Basel, Switzerland), FBS and trypsin were
purchased from Gibco®/Invitrogen Corporation (New York, NY, USA), BSA, and mounting medium
was from Millipore Sigma (Burlington, MA, USA). Draq5™and DAB Quanto were purchased from
Thermo Fisher Scientific (Waltham, MA, USA), while the MTT powder was obtained from Sigma
Aldrich Kft. (Budapest, Hungary). hGnRH-I-R primary antibody and GnRH-R polyclonal antibody
Int. J. Mol. Sci. 2019, 20, 5027 10 of 17
were purchased from Proteintech™ (Rosemont, IL, USA) and Alexa Fluor 594 conjugated secondary
antibody was from Jackson ImmunoResearch Inc. (Ely, UK).
4.2. Patients
Altogether, 60 therapy naive patients, who were diagnosed with squamous cell carcinoma of
the oropharynx, hypopharynx, and larynx at the Department of Oto-Rhino-Laryngology and Head
and Neck Surgery, Semmelweis University between 2012 and 2014, were consecutively enrolled.
All subjects gave their informed consent for inclusion before they participated in the study. The study
was conducted in accordance with the Declaration of Helsinki and the protocol was approved by the
Semmelweis University’s Regional, Institutional Scientific, and Research Ethics Committee (ethical
license No: 105/2014). The most important characteristics of our cohort are shown in Table 4.
Table 4. Patient characteristics at time of diagnosis.
Variable No. of Patients
Total no. of patients 60
Sex
Male 51
Female 9
Age (year)
Mean 58.45 (41–77)
Localization
Oropharynx 19
Larynx 24
Hypopharynx 16
Lingua 1
TNM 1 stage
I 6
II 11
III 15
IV A 20
IV B 3
IV C 5
1 TNM: tumor, node, and metastasis, UICC TNM 7th edition.
4.3. Tissue Microarray (TMA) and Immunohistochemistry
TMA blocks containing 2 mm diameter cores of formalin-fixed paraffin-embedded tissue samples
were created using the TMA Master tool (3DHISTECH Kft, Budapest, Hungary). Tissue sections (4 µm)
were cut on adhesion slides and were stained with hematoxylin and eosin and GnRH-R. The protocol
of the staining method was carried out as described previously [47].
Immunohistochemistry was performed in TMA sections following routine dewaxing rehydration.
For antigen retrieval, the samples were boiled in Tris-EDTA buffer solution (pH 9.0) for 58 min.
Endogenous peroxidase activity was blocked using 3% H2O2 in methanol for 15 min. Immunostaining
included the following sequential incubation steps: Usage of 3% BSA in 0.1 M Tris-buffered saline with
Tween® 20 pH 7.4 (TBST) as a protein block for 15 min, the optimally diluted primary antibody (1:100)
overnight (16 h), and the HISTOLS-MR-T HRP Polymer reagent for 40 min. Samples were washed after
each incubation step for 10 min in TBST. Peroxidase activity was visualized using DAB Quanto for 1
min under microscopic control. Finally, nuclear counterstaining was applied using hematoxylin and
eosin. All incubations were performed in humidity chambers at room temperature. Immunostained
slides were digitalized applying a Pannoramic Scan instrument (3DHISTECH Kft, Budapest, Hungary).
The histologic evaluation and the scoring of immunoreactions were done by 2 independent assessors
using the Pannoramic Viewer software.
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An alternative 3-grade scoring approach, applied in several earlier studies for the evaluation
of EGFR protein expression [48,49], was used for the evaluation of GnRH-R protein expression.
Briefly, the percentage of stained cells was multiplied by the grade intensity of staining (in four grades:
1, negative; 2, weak; 3, moderate; 4, intense), which resulted in a value between 0 and 400. Cores
with scores 0 to 200 (1), 201 to 300 (2), and 301 to 400 (3) were referred to as weak, medium, or strong
protein expression, respectively. For statistical analysis, scores were dichotomized along different
threshold values. The most reproducible threshold for the assessor was set up when scores of 1 and
2 were considered low/negative protein expression, whereas scores of 3 were taken high/positive
protein expression.
4.4. Statistical Analysis
For patient data, statistical analysis was performed using Statistica 13 (TIBCO Software Inc., Palo
Alto, CA, USA). The Pearson χ2 tests and the Fisher’s exact tests were used to test correlations between
discrete variables. In case of survival analysis, Kaplan–Meier estimation with log-rank test as well
as univariate and multivariate regression were applied. All tests were two-sided and p-values <0.05
were considered statistically significant. Tumor localization, tumor size, stage, lymph node metastasis,
and the biomarkers listed above were used in the analysis.
4.5. Peptide Synthesis
All peptides were synthesized manually using solid phase peptide synthesis according to standard
Fmoc/tBu strategy. The Fmoc deprotection was performed with 2% piperidine + 2% DBU in DMF
(2 + 2 + 5 + 10 min), then the α-Fmoc-protected amino acid derivatives were coupled with DIC and
HOBt (3 eq each to the resin capacity).
4.5.1. GnRH-I[6D-Lys] (Compound 1)
The GnRH-I modified with D-Lys in position 6 (<EHWSYkLRPG-NH2) was synthesized on
Fmoc-Rink Amide MBHA resin (0.69 mmol/g coupling capacity). After the completion of the synthesis,
the decapeptide was cleaved from the resin using a mixture of 95% TFA, 2.5% H2O, and 2.5% TIS for
1.5 h at room temperature. The crude peptide was precipitated into ice-cold diethyl ether, centrifuged,
and washed three times with diethyl ether. The precipitate was dissolved in a mixture of acetonitrile
and water prior lyophilization, then the peptide was purified by preparative RP-HPLC and analyzed
by ESI-MS.
4.5.2. GnRH-I[4Lys(Bu),6D-Lys] (Compound 2) and GnRH-II[4Lys(Bu),6D-Lys] (Compound 3)
Analogs modified with butyrylated lysine (Lys(Bu)) in position 4 and with D-Lys in position 6
(GnRH-I: <EHWK(Bu)YkLRPG-NH2 and GnRH-II: <EHWK(Bu)HkWYPG-NH2) were synthesized
similarly as described above. In these cases, Fmoc-Lys(Dde)-OH was incorporated into the peptide in
position 4. After completion of the protected decapeptides, the Dde group of 4Lys was removed on the
resin by 2% N2H4·H2O in DMF (8 × 5 min), then the acylation was performed using butyric anhydride
and DIPEA (3 eq each to the amino group) in DMF for 2 h. The peptides were cleaved from the resin
and analyzed as described above.
4.5.3. GnRH-III[4Lys(Bu),6Asp(OMe)] (Compound 4)
GnRH-III analog modified with Lys(Bu) in position 4 and with aspartic acid methyl ester
(Asp(OMe)) in position 6 (<EHWK(Bu)HD(OMe)WKPG-NH2) was synthesized similarly as described
above, but since the methyl ester group is labile under basic conditions, Fmoc-Lys(Mtt)-OH
was used in position 4. Furthermore, the mixture used for Fmoc deprotection was changed to
0.1 M HOBt + 2% piperidine + 2% DBU in DMF to avoid the methyl ester cleavage and the subsequent
succinimide bond formation. After the completion of the backbone synthesis, the Mtt group was
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removed from the ε-amino group by 2% TFA + 2% TIS in DCM (2 + 2 + 5 + 10 + 30 min) and the lysine
was butyrylated (with butyric anhydride and DIPEA; 3 eq each to the amino group). The peptide was
cleaved from the resin and analyzed as described above.
4.6. Conjugate Synthesis (Compounds 5–8)
The peptides, protoporphyrin IX and PyBOP (1:1:3 eq), were dissolved in DMF, then DIPEA
(6 eq) was added to the mixture. The reaction was stirred for 16 h at room temperature in darkness.
The bioconjugates were purified by preparative RP-HPLC and the pure conjugates were analyzed
by analytical RP-HPLC and ESI-MS (analytical data, HPLC chromatograms and MS spectra of the
produced conjugates are presented in Table S1 and Figures S1–S4 in Supplementary Materials)
4.7. RP-HPLC
The crude peptides and the bioconjugates were purified on a Knauer 2501 HPLC system (H. Knauer,
Bad Homburg, Germany). A preparative Phenomenex Luna C18 column (250 × 21.2 mm) with 10 µm
silica (100 Å pore size) was used for the crude peptides, while a Phenomenex Jupiter C4 column
(250 × 10 mm) with 10 µm silica (300 Å pore size) was used for the bioconjugates (Torrance, CA, USA).
Linear gradient elution (0 min 5% B; 5 min 5% B; 50 min 80% B) with eluent A (0.1% TFA in water)
and eluent B (0.1% TFA in acetonitrile-water 80:20, v/v) was used at a flow rate of 16 mL/min for the
peptides and linear gradient elution (0 min 15% B; 5 min 15% B; 50 min 60% B) with eluent A (0.1%
TFA in water) and eluent B (0.1% TFA in acetonitrile) was used at a flow rate of 4 mL/min for the
bioconjugates. Peaks were detected at 220 nm.
Analytical RP-HPLC runs were performed on a Knauer 2501 HPLC system using a Macherey–Nagel
Nucleosil C18 column (250 × 4.6 mm) with 5 µm silica (100 Å pore size). Linear gradient elution
(0 min 2% B; 5 min 2% B; 30 min 90% B) with eluent A (0.1% TFA in water) and eluent B (0.1% TFA in
acetonitrile) was used at a flow rate of 1 mL/min. Peaks were detected at 220 nm.
4.8. Mass Spectrometry
Electrospray (ESI)-mass spectrometric measurements were performed on an Esquire 3000+ ion
trap mass spectrometer (Bruker Daltonics, Bremen, Germany). Spectra were acquired in positive mode
in the 50–2000 m/z range. Samples were dissolved in a 0.1% acetic acid containing acetonitrile–water
(50:50, v/v) mixture.
4.9. Radioligand Binding Assay
Displacement studies using 125I-labelled GnRH-I agonist triptorelin for the determination of the
receptor binding potency of the synthesized compounds were performed on human pituitary and
human prostate cancer cells. Tissue samples derived by autopsy from normal human pituitary (anterior
lobe) and human prostate cancer cells were obtained from a patient at the time of initial surgical
treatment. The collection and the use of these specimens for our studies are approved by the local
Institutional Ethics Committee. The binding affinities of the GnRH-analogs and GnRH-protoporphyrin
conjugates to GnRH-R-I were determined by displacement of [125I]-[6D-Trp]-GnRH-I performing
an in vitro ligand competition assay. The assay was performed as described earlier [13–15,30,41,50].
In brief, membrane homogenates containing 50–160 µg protein were incubated in duplicate with
60–80,000 cpm [125I]-[6D-Trp]-GnRH-I in the presence of increasing concentrations (10−12–10−6 M) of
nonradioactive unlabeled peptides/conjugates as competitors in a total volume of 150 µL of binding
buffer. At the end of the incubation, 125 µL aliquots of suspension were transferred onto the top of 1 mL
of ice-cold binding buffer containing 1.5% BSA in microcentrifuge tubes. The tubes were centrifuged
at 12,000× g for 3 min at 4 ◦C. Supernatants were aspirated and the pellet was counted in a gamma
counter. Protein concentration was determined by the method of Bradford, using a Bio-Rad protein
assay kit (Bio-Rad Laboratories, Hercules, CA, USA). The LIGAND-PC computerized curve-fitting
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program of Munson and Rodbard was used to determine the receptor binding characteristics and
IC50 values.
4.10. UV-Vis Spectroscopy
UV-Vis spectra were recorded between 200–800 nm using a BioTek Synergy 2 Multi-Mode Reader.
The 50 µM solutions were prepared in PBS:acetonitrile (1:1, v/v) containing 1% DMSO.
4.11. Cell Cultures
Detroit-562 human pharyngeal cells were purchased from the American Type Culture Collection
(Manassas, VA, USA). Cells were cultured in EMEM medium, containing 10% FBS, 1% sodium pyruvate,
and 1% MycoZap, at 37 ◦C in a humidified 5% CO2 atmosphere. For the experiments, Detroit-562
cells with passage number 12 were thawed and serially passaged until passage 35. For new passages,
cells were seeded into T25 flasks and grown to 80–90% confluence. Then the cells were rinsed with
phosphate buffered saline and removed by adding Trypsin–EDTA. The cell number was established
using a hemocytometer.
4.12. Confocal Laser Scanning Microscopy
Cells were seeded on Ibidi® µ-Slide 8-well microscopic slides (104 cells/well) 48 h prior to the
treatment. Cells were fixed with 4% paraformaldehyde for 10 min and washed twice with PBS.
In contrast of the membrane GnRH-R investigation, cells were also permeabilized with 0.1% (v/v) Triton
X-100 PBS solution for 10 min in case of the total GnRH-R protein level determination. After blocking
with 5% BSA in PBS for 30 min, the cells were incubated with hGnRH-I-R primary antibody (dilution:
1:100) and subsequently with Alexa Fluor 594 conjugated secondary antibody (dilution: 1:300) for 1-1 h
at 25 ◦C. Then, Draq5™ fluorescent probe solution (10 µM) was added to the cells for 10 min. Cells
were washed three times with PBS and a few drops of mounting media was added. Images of cells
were acquired with confocal laser microscope (Zeiss Confocal LSM 710, Carl Zeiss AG, Oberkochen,
Germany; objective: Plan-Apochromat 63x/1.40 Oil DIC M27; pinhole: 1 AU; laser wavelength: 543 nm
10.0%, 633 nm 4.0%; detection wavelength: 602–631 nm, 676–758 nm).
4.13. In Vitro Cell Viability Assay
Cells were seeded to 96-well plates (6·× 103 cells/well) 48 h prior to the treatment. The cells were
treated with the peptides (10 µM) and conjugates (0.025–10 µM) in darkness. Stock solutions of the
compounds were prepared in DMSO (5 mM) and all dilutions were made to contain 0.2% DMSO final
concentration. The control wells were treated with medium or 0.2% DMSO containing medium. After 1,
3, or 5 h, the cells were washed once with medium, irradiated for 0, 2, 10, or 30 min and incubated
for a further 72 h. The irradiation was performed by an Oriel type 250 W Quartz Tungsten Halogen
lamp (Newport Corporation, CA, USA) with a 550 nm emission maximum. The light was filtered to
exclude UV and IR components. The fluence rate was determined by a 10 A-P Nova laser power/energy
monitor (Ophir, Optronix, Jerusalem, Israel) using the pyro-electric detector. Then, the MTT-test was
performed according to the manufacturer’s instructions. Each point was measured using 3 parallels
and each experiment was repeated twice.
4.14. Statistical Evaluation of In Vitro Viability Data
For in vitro cell viability data, statistical analysis was performed using the multiple t-test algorithm
of GraphPad Prism 8.2.0 software (GraphPad Software Inc., San Diego, CA, USA). Statistical significance
was determined using the Holm–Sidak method. Each row was analyzed individually, without assuming
a consistent SD. Significance levels correspond to * p < 0.05; ** p < 0.01; and *** p < 0.001.
Supplementary Materials: Supplementary Materials can be found at http://www.mdpi.com/1422-0067/20/20/
5027/s1.
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Abbreviations
ALA δ-aminolevulinic acid
BSA Bovine serum albumin
Dau Daunorubicin
DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene
DCM Dichloromethane
Dde N-(1-(4,4-Dimethyl-2,6-dioxocyclohexylidene)ethyl)
DIC N,N′-Diisopropylcarbodiimide
DIPEA Diisopropylethylamine
DMF N,N-Dimethylformamide
DSS Disease-specific survival
<E pyroglutamic acid
EGFR Epidermal growth factor receptor
EMEM Eagle’s Minimum Essential Medium
FBS Fetal bovine serum
Fmoc 9-Fluorenylmethyloxycarbonyl
FSH Follicle stimulating hormone
GnRH Gonadotropin-releasing hormone
GnRH-R Gonadotropin-releasing hormone receptor
HOBt 1-Hydroxybenzotriazole hydrate
LH Luteinizing hormone
Mtt 4-Methyltrityl
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NHSCC Head and neck squamous cell carcinomas
PBS Phosphate-buffered saline
PDT Photodynamic therapy
PpIX Protoporphyrin IX
PyBOP Benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate
TFA Trifluoroacetic acid
TIS Triisopropylsilane
TMA Tissue Microarray
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